Lin Li,David Coghill,Arvid Sjölander,Honghui Yao,Le Zhang,Ralf Kuja-Halkola,Isabell Brikell,Paul Lichtenstein,Brian M D'Onofrio,Henrik Larsson,Zheng Chang
{"title":"随着时间的推移,注意力缺陷/多动障碍药物处方的增加和现实世界的结果。","authors":"Lin Li,David Coghill,Arvid Sjölander,Honghui Yao,Le Zhang,Ralf Kuja-Halkola,Isabell Brikell,Paul Lichtenstein,Brian M D'Onofrio,Henrik Larsson,Zheng Chang","doi":"10.1001/jamapsychiatry.2025.1281","DOIUrl":null,"url":null,"abstract":"Importance\r\nThe prescription of attention-deficit/hyperactivity disorder (ADHD) medications has risen substantially in many countries over the last 20 years. However, whether the real-world benefits of ADHD medications change with increased prescription rates within a society remains unknown.\r\n\r\nObjective\r\nTo examine whether the associations between ADHD medications and real-world outcomes (self-harm, unintentional injury, traffic crashes, and crime) change as prescription rates rise.\r\n\r\nDesign, Setting, and Participants\r\nThis study used a self-controlled case series design. It was a population-based study using Swedish National Registers that included individuals who used ADHD medications in Sweden between 2006 and 2020. Data were analyzed from October 2023 to November 2024.\r\n\r\nExposure\r\nADHD medication use.\r\n\r\nMain Outcomes and Measures\r\nRates of self-harm, unintentional injury, traffic crashes, and crime during medicated vs nonmedicated periods. The associations between ADHD medication and these real-world outcomes were examined across 3 time periods, 2006 to 2010, 2011 to 2015, and 2016 to 2020, during which ADHD medication prevalence increased from 0.6% to 2.8%.\r\n\r\nResults\r\nThere were 247 420 individuals identified (99 361 females [40.2%] and 148 059 males [59.8%]) aged 4 to 64 years in Sweden who used ADHD medications between 2006 and 2020. ADHD medication was consistently associated with lower risks for self-harm (incidence rate ratio [IRR] ranged from 0.77; 95% CI, 0.73-0.81 to 0.85; 95% CI, 0.82-0.88), unintentional injury (IRR ranged from 0.87; 95% CI, 0.84-0.89 to 0.93, 95% CI, 0.91-0.95), traffic crashes (IRR ranged from 0.71; 95% CI, 0.67-0.77 to 0.87; 95% CI, 0.83-0.91), and crime (IRR ranged from 0.73; 95% CI, 0.71-0.75 to 0.84; 95% CI, 0.82-0.85) across different age groups, sexes, and over time. However, the associations between ADHD medication use and lower risks of unintentional injury (P value for trend < .01), traffic crashes (P value for trend < .01), and crime (P value for trend < .01) appear to weaken over time as prescription rates increased. Changes in age and sex distribution of individuals receiving ADHD medication did not fully explain the weakening trend for unintentional injury and traffic crashes.\r\n\r\nConclusions and Relevance\r\nIn this study, ADHD medication remained associated with reduced risks of several serious real-world outcomes. However, the magnitude of these associations appears to have decreased alongside rising prescription rates over time. Thus, it is important to regularly evaluate medication use in different patient populations.","PeriodicalId":14800,"journal":{"name":"JAMA Psychiatry","volume":"8 1","pages":""},"PeriodicalIF":17.1000,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over Time.\",\"authors\":\"Lin Li,David Coghill,Arvid Sjölander,Honghui Yao,Le Zhang,Ralf Kuja-Halkola,Isabell Brikell,Paul Lichtenstein,Brian M D'Onofrio,Henrik Larsson,Zheng Chang\",\"doi\":\"10.1001/jamapsychiatry.2025.1281\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Importance\\r\\nThe prescription of attention-deficit/hyperactivity disorder (ADHD) medications has risen substantially in many countries over the last 20 years. However, whether the real-world benefits of ADHD medications change with increased prescription rates within a society remains unknown.\\r\\n\\r\\nObjective\\r\\nTo examine whether the associations between ADHD medications and real-world outcomes (self-harm, unintentional injury, traffic crashes, and crime) change as prescription rates rise.\\r\\n\\r\\nDesign, Setting, and Participants\\r\\nThis study used a self-controlled case series design. It was a population-based study using Swedish National Registers that included individuals who used ADHD medications in Sweden between 2006 and 2020. Data were analyzed from October 2023 to November 2024.\\r\\n\\r\\nExposure\\r\\nADHD medication use.\\r\\n\\r\\nMain Outcomes and Measures\\r\\nRates of self-harm, unintentional injury, traffic crashes, and crime during medicated vs nonmedicated periods. The associations between ADHD medication and these real-world outcomes were examined across 3 time periods, 2006 to 2010, 2011 to 2015, and 2016 to 2020, during which ADHD medication prevalence increased from 0.6% to 2.8%.\\r\\n\\r\\nResults\\r\\nThere were 247 420 individuals identified (99 361 females [40.2%] and 148 059 males [59.8%]) aged 4 to 64 years in Sweden who used ADHD medications between 2006 and 2020. ADHD medication was consistently associated with lower risks for self-harm (incidence rate ratio [IRR] ranged from 0.77; 95% CI, 0.73-0.81 to 0.85; 95% CI, 0.82-0.88), unintentional injury (IRR ranged from 0.87; 95% CI, 0.84-0.89 to 0.93, 95% CI, 0.91-0.95), traffic crashes (IRR ranged from 0.71; 95% CI, 0.67-0.77 to 0.87; 95% CI, 0.83-0.91), and crime (IRR ranged from 0.73; 95% CI, 0.71-0.75 to 0.84; 95% CI, 0.82-0.85) across different age groups, sexes, and over time. However, the associations between ADHD medication use and lower risks of unintentional injury (P value for trend < .01), traffic crashes (P value for trend < .01), and crime (P value for trend < .01) appear to weaken over time as prescription rates increased. Changes in age and sex distribution of individuals receiving ADHD medication did not fully explain the weakening trend for unintentional injury and traffic crashes.\\r\\n\\r\\nConclusions and Relevance\\r\\nIn this study, ADHD medication remained associated with reduced risks of several serious real-world outcomes. However, the magnitude of these associations appears to have decreased alongside rising prescription rates over time. Thus, it is important to regularly evaluate medication use in different patient populations.\",\"PeriodicalId\":14800,\"journal\":{\"name\":\"JAMA Psychiatry\",\"volume\":\"8 1\",\"pages\":\"\"},\"PeriodicalIF\":17.1000,\"publicationDate\":\"2025-06-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1001/jamapsychiatry.2025.1281\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamapsychiatry.2025.1281","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Increased Prescribing of Attention-Deficit/Hyperactivity Disorder Medication and Real-World Outcomes Over Time.
Importance
The prescription of attention-deficit/hyperactivity disorder (ADHD) medications has risen substantially in many countries over the last 20 years. However, whether the real-world benefits of ADHD medications change with increased prescription rates within a society remains unknown.
Objective
To examine whether the associations between ADHD medications and real-world outcomes (self-harm, unintentional injury, traffic crashes, and crime) change as prescription rates rise.
Design, Setting, and Participants
This study used a self-controlled case series design. It was a population-based study using Swedish National Registers that included individuals who used ADHD medications in Sweden between 2006 and 2020. Data were analyzed from October 2023 to November 2024.
Exposure
ADHD medication use.
Main Outcomes and Measures
Rates of self-harm, unintentional injury, traffic crashes, and crime during medicated vs nonmedicated periods. The associations between ADHD medication and these real-world outcomes were examined across 3 time periods, 2006 to 2010, 2011 to 2015, and 2016 to 2020, during which ADHD medication prevalence increased from 0.6% to 2.8%.
Results
There were 247 420 individuals identified (99 361 females [40.2%] and 148 059 males [59.8%]) aged 4 to 64 years in Sweden who used ADHD medications between 2006 and 2020. ADHD medication was consistently associated with lower risks for self-harm (incidence rate ratio [IRR] ranged from 0.77; 95% CI, 0.73-0.81 to 0.85; 95% CI, 0.82-0.88), unintentional injury (IRR ranged from 0.87; 95% CI, 0.84-0.89 to 0.93, 95% CI, 0.91-0.95), traffic crashes (IRR ranged from 0.71; 95% CI, 0.67-0.77 to 0.87; 95% CI, 0.83-0.91), and crime (IRR ranged from 0.73; 95% CI, 0.71-0.75 to 0.84; 95% CI, 0.82-0.85) across different age groups, sexes, and over time. However, the associations between ADHD medication use and lower risks of unintentional injury (P value for trend < .01), traffic crashes (P value for trend < .01), and crime (P value for trend < .01) appear to weaken over time as prescription rates increased. Changes in age and sex distribution of individuals receiving ADHD medication did not fully explain the weakening trend for unintentional injury and traffic crashes.
Conclusions and Relevance
In this study, ADHD medication remained associated with reduced risks of several serious real-world outcomes. However, the magnitude of these associations appears to have decreased alongside rising prescription rates over time. Thus, it is important to regularly evaluate medication use in different patient populations.
期刊介绍:
JAMA Psychiatry is a global, peer-reviewed journal catering to clinicians, scholars, and research scientists in psychiatry, mental health, behavioral science, and related fields. The Archives of Neurology & Psychiatry originated in 1919, splitting into two journals in 1959: Archives of Neurology and Archives of General Psychiatry. In 2013, these evolved into JAMA Neurology and JAMA Psychiatry, respectively. JAMA Psychiatry is affiliated with the JAMA Network, a group of peer-reviewed medical and specialty publications.